| STATE
COLLEGE, Pa.--(BUSINESS WIRE)--May 19, 2004--NanoHorizons,
an emerging leader in nanoscale material and device
technologies, is a recipient of the 2004 Frost &
Sullivan Award for Excellence in Technology. This award
has been presented to NanoHorizons in recognition of
its innovativeness in applying the science of nanotechnology
to drug discovery. The company has developed novel nanotechnology-based
QuickMass(TM) targets for mass spectrometry. QuickMass
targets are designed for use in applications that require
the identification of small molecules, and are particularly
effective in analyzing drug candidates produced by combinatorial
chemistry.
QuickMass targets enable quick and precise chemical
analysis of small molecules by matrix-free laser desorption
mass spectrometry. Using conventional MALDI (Matrix
Assisted Laser Desorption Ionization) mass spectrometers,
the unique QuickMass targets produce mass spectra
faster than the LC/MS technique. QuickMass targets
eliminate the need for matrix compounds, normally
used to facilitate laser desorption and ionization
of small molecules. Since matrix compounds are not
required, a clean, reproducible spectrum can be produced
from samples deposited on a QuickMass target with
a standard MALDI mass spectrometer. By eliminating
background peaks of interfering matrix compounds,
good analyses of drug candidates from combinatorial
chemistry laboratories can be produced more quickly.
QuickMass targets can also be used in other phases
of the drug discovery process, such as ADME (Adsorption,
Distribution, Metabolism, and Excretion) analyses.
This technique offers an increased sample throughput
and can deliver up to an 80% increase in research
laboratory productivity.
QuickMass
targets use a non-porous thin film surface, a direct
product of NanoHorizons' research into thin film nanostructures
and nanodevices. The thin film in QuickMass allows
laser energy to be rapidly transferred to the analyte
molecules in the ionization process. The result is
effective small molecule desorption, ionization and
mass spectroscopy without the need for an interfering
matrix. An added advantage of using this non-porous
film is the avoidance of low mass contaminant trapping,
which can further complicate the analysis process.
These advantages are all achieved while using the
same methodologies and mass spectrometry equipment
as conventional MALDI.
QuickMass
technology is starting to gain critical acceptance,
as is exemplified by the recent announcement of collaboration
between NanoHorizons and Kratos Analytical Ltd. (a
wholly owned subsidiary of the Shimadzu Corporation
of Kyoto, Japan). As part of this program, Kratos
will present QuickMass technology to the market by
strategically integrating it with its currently available
mass spectrometers. This collaboration is expected
to enhance Kratos/Shimadzu's efforts to provide equipment
and targets for diverse applications in the chemical/pharmaceutical
sectors.
"We
are most pleased to receive this award. It recognizes
our success in developing a significant breakthrough
product which enables drug discovery research to be
more productive and cost effective," said Robert
F. Burlinson, President and C.E.O. of NanoHorizons.
"NanoHorizons
has demonstrated the ability to successfully apply
the emerging science of nanotechnology to drug discovery.
The company's QuickMass(TM) technology platform avoids
the encumbrances of using a matrix material while
significantly reducing the time required for analysis
of small drug molecules. This will, wherever used,
substantially enhance the throughput of drug screening
processes and ultimately help bring drugs to market
faster. It is in recognition of this research excellence
and business potential of the technology that NanoHorizons
Inc. has been bestowed with the Frost & Sullivan
Award for Excellence in Technology," said Giridhar
Rao, industry analyst with Frost & Sullivan.
About
NanoHorizons, Inc.
NanoHorizons,
Inc. was founded in 2002 with a business focus on
nanotechnology applications in the drug discovery,
microelectronics and health care industries. The company
has licensed a comprehensive portfolio of nanotechnology
Intellectual Property from the Pennsylvania State
University.
The
initial product offering, QuickMass(TM) matrix free
laser desorption plates, addresses the need for more
cost effective pharmaceutical research and increased
drug discovery capacity. Additional commercial initiatives
are being pursued to meet needs for fast, high-sensitivity
respiration monitors as well as humidity and gas sensors.
Additionally, a manufacturing process used to place
high performance logic, sensors, displays, MEMS and
optoelectronics on inexpensive or mechanically flexible
substrates offers licensing opportunities.
For
more information, visit www.nanohorizons.com or write
to us at info@nanohorizons.com
About
Frost & Sullivan
Founded
in 1961, Frost & Sullivan is recognized as a global
leader in growth consulting. Frost & Sullivan
Awards are presented to companies that demonstrate
excellence in their industry, commending the diligence,
commitment, and innovative business strategies required
to advance in the global marketplace. Frost &
Sullivan rigorously analyzes specific criteria to
determine award recipients in a vast variety of market
industries and landscapes. For further information,
visit www.frost.com.
Award
Description
Frost
& Sullivan's Excellence in Technology Award is
bestowed upon the company that has pioneered the development
and introduction of an innovative technology into
the market; a technology that has either impacted
or has the potential to impact several market sectors.
This award recognizes a company's successful technology
development that is expected to bring significant
contributions to the industry in terms of adoption,
change, and competitive posture. It also recognizes
the overall technical excellence of a company and
its commitment towards technology innovation.
|